Novartis: secures rights to targeted therapies

(CercleFinance.com) - Novartis announced today that it has obtained exclusive worldwide rights to develop and commercialise therapeutic applications for a library of fibroblast activating protein (FAP) targeting agents, including FAPI-46 and FAPI-74.


These rights were obtained as part of an agreement with iTheranostics, which also includes co-exclusive rights for Novartis to develop imaging applications for these assets that were originally developed at Heidelberg University.

Novartis explains that FAP is expressed at low levels in most normal adult tissues, but overexpressed in common cancers, particularly on cancer-associated fibroblasts that form the tumour stroma.


Copyright (c) 2021 CercleFinance.com. All rights reserved.